Welcome to our dedicated page for Agilent Technologies news (Ticker: A), a resource for investors and traders seeking the latest updates and insights on Agilent Technologies stock.
Agilent Technologies Inc. reports developments across analytical and clinical laboratory technologies, including instruments, software, services and scientific expertise used by life science, diagnostics, applied, biopharmaceutical, chemical, advanced materials, clinical lab, environmental, food, forensics, academic and government customers. Company updates commonly address financial results, product launches, laboratory workflows and changes in senior legal, governance and compliance leadership.
Recent Agilent news has highlighted the BioTek Cytation 9 cell imaging multimode reader for cell-based research and high-content screening, cancer research and diagnostics workflows, and FDA-approved companion diagnostic indications for PD-L1 IHC 22C3 pharmDx, including use in identifying certain esophageal or gastroesophageal junction carcinoma patients who may be eligible for KEYTRUDA.
Padraig McDonnell has assumed the role of Agilent CEO, succeeding Mike McMullen. McDonnell is the fourth CEO in Agilent's history. He brings a proven record of success, having served as president of the Agilent CrossLab Group (ACG) and chief commercial officer. McDonnell's leadership skills and customer focus are expected to drive Agilent's growth and success in the future.
Agilent Technologies Inc. (NYSE: A) has introduced the NovoCyte Opteon Spectral Flow Cytometer, a cutting-edge system that revolutionizes flow cytometry by offering advanced spectral capabilities and user-friendly design. This new addition to the NovoCyte family features three to five lasers, up to 73 detectors, and the ability to analyze over 40 markers simultaneously, providing researchers with unprecedented precision and flexibility in flow cytometry assays. The NovoCyte Opteon will be officially unveiled at the CYTO 2024 Conference in May 2024, marking a decade of innovation in the NovoCyte platform.
Agilent Technologies, Inc. (NYSE: A) has appointed Simon May as the president of the Diagnostics and Genomics Group (DGG). May, previously from Bio-Rad Laboratories, brings a wealth of experience to Agilent. He will be joining the company on May 6th. The CEO-elect, Padraig McDonnell, expressed excitement about May's technical expertise, experience, and focus on strategy. May's background includes roles at Bio-Rad and Thermo Fisher Scientific, with academic credentials from the University of Liverpool.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.